Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472112 | 1.00 | PLAU (0.39) | PLAUIDO1HTR2AKDM1AANPEP | |
| SCHEMBL4407901 | 0.73 | ANPEP (0.33) | PLAUIDO1ANPEP | |
| SCHEMBL11004524 | 0.73 | ACHE (0.41) | IDO1 | |
| SCHEMBL4513001 | 0.73 | IDO1 (0.32) | PLAUIDO1 | |
| SCHEMBL6962983 | 0.73 | ANPEP (0.33) | PLAUIDO1ANPEP | |
| SCHEMBL8630503 | 0.70 | PRCP (0.37) | HTR2AKDM1ASIGMAR1 | |
| SCHEMBL9510934 | 0.70 | ANPEP (0.39) | ANPEPSIGMAR1 | |
| SCHEMBL6326122 | 0.70 | ACHE (0.34) | IDO1 | |
| SCHEMBL4518955 | 0.68 | PNMT (0.39) | — | |
| SCHEMBL275458 | 0.67 | HTR2A (0.45) | HTR2AKDM1AANPEPSIGMAR1AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | claimed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | PLAU 774/4885IDO1 1246/4885HTR2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.